The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
Open accessAbstract
BACKGROUND: -agonist may be an alternative to conventional treatment strategies. METHODS: We conducted a 52-week, double-blind trial involving patients 12 years of age or older with mild asthma. Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed (budesonide-formoterol group), or twice-daily budesonide (200 μg) plus terbutaline used as needed (budesonide maintenance group). The primary objective was to investigate the superiority of as-needed budesonide-formoterol to as-needed terbutaline with regard to electronically recorded weeks with well-controlled asthma. RESULTS: A total of 3849 patients underwent randomization, and 3836 (1277 in the terbutaline group, 1277 in the budesonide-formoterol group, and 1282 in the budesonide maintenance group) were included in the full analysis and safety data sets. With respect to the mean percentage of weeks with well-controlled asthma per patient, budesonide-formoterol was superior to terbutaline (34.4% vs. 31.1% of weeks; odds ratio, 1.14; 95% confidence interval [CI], 1.00 to 1.30; P=0.046) but inferior to budesonide maintenance therapy (34.4% and 44.4%, respectively; odds ratio, 0.64; 95% CI, 0.57 to 0.73). The annual rate of severe exacerbations was 0.20 with terbutaline, 0.07 with budesonide-formoterol, and 0.09 with budesonide maintenance therapy; the rate ratio was 0.36 (95% CI, 0.27 to 0.49) for budesonide-formoterol versus terbutaline and 0.83 (95% CI, 0.59 to 1.16) for budesonide-formoterol versus budesonide maintenance therapy. The rate of adherence in the budesonide maintenance group was 78.9%. The median metered daily dose of inhaled glucocorticoid in the budesonide-formoterol group (57 μg) was 17% of the dose in the budesonide maintenance group (340 μg). CONCLUSIONS: In patients with mild asthma, as-needed budesonide-formoterol provided superior asthma-symptom control to as-needed terbutaline, assessed according to electronically recorded weeks with well-controlled asthma, but was inferior to budesonide maintenance therapy. Exacerbation rates with the two budesonide-containing regimens were similar and were lower than the rate with terbutaline. Budesonide-formoterol used as needed resulted in substantially lower glucocorticoid exposure than budesonide maintenance therapy. (Funded by AstraZeneca; SYGMA 1 ClinicalTrials.gov number, NCT02149199 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., & Pedersen, S. E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-033oc · Cited by 1,594
Self-citationBudesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma
O'Byrne, P. M., Bisgaard, H., Godard, P. P., Pistolesi, M., Palmqvist, M., Zhu, Y., Ekström, T., & Bateman, E. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-884oc · Cited by 657
Self-citationCompliance, Adherence, and Concordance
Horne, R. (2006) · Chest · doi:10.1378/chest.130.1_suppl.65s · Cited by 602
Price, D., Fletcher, M., & van der Molen, T. (2014) · npj Primary Care Respiratory Medicine · doi:10.1038/npjpcrm.2014.9 · Cited by 554
As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
Bateman, E. D., Reddel, H. K., O’Byrne, P. M., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Siwek-Posluszna, A., & FitzGerald, J. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715275 · Cited by 516
Self-citationAttitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study
Partridge, M. R., van der Molen, T., Myrseth, S.-E., & Busse, W. W. (2006) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-6-13 · Cited by 495
Rabe, K. F., Atienza, T., Magyar, P., Larsson, P., Jorup, C., & Lalloo, U. G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69284-2 · Cited by 431
Self-citationRescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma
Papi, A., Canonica, G. W., Maestrelli, P., Paggiaro, P., Olivieri, D., Pozzi, E., Crimi, N., Vignola, A. M., Morelli, P., Nicolini, G., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063861 · Cited by 365
Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma
Suissa, S. (2002) · Thorax · doi:10.1136/thorax.57.10.880 · Cited by 322
Airway Inflammation in Mild Intermittent and in Persistent Asthma
VIGNOLA, A. M., CHANEZ, P., CAMPBELL, A. M., SOUQUES, F., LEBEL, B., ENANDER, I., & BOUSQUET, J. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.96-08040 · Cited by 318
Cited by
Porsbjerg, C., Melén, E., Lehtimäki, L., & Shaw, D. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02125-0 · Cited by 575
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02730-2021 · Cited by 537
Self-citationAs-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
Bateman, E. D., Reddel, H. K., O’Byrne, P. M., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Siwek-Posluszna, A., & FitzGerald, J. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715275 · Cited by 516
Self-citationGlobal Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Self-citationImproving lung health in low-income and middle-income countries: from challenges to solutions
Meghji, J., Mortimer, K., Agusti, A., Allwood, B. W., Asher, I., Bateman, E. D., Bissell, K., Bolton, C. E., Bush, A., Celli, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00458-x · Cited by 470
Self-citationControlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
Beasley, R., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., Harrison, T., Houghton, C., Oldfield, K., Papi, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901963 · Cited by 466
Self-citationReddel, H. K., FitzGerald, J. M., Bateman, E. D., Bacharier, L. B., Becker, A., Brusselle, G., Buhl, R., Cruz, A. A., Fleming, L., Inoue, H., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01046-2019 · Cited by 390
Self-citationKey recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update
Levy, M. L., Bacharier, L. B., Bateman, E., Boulet, L.-P., Brightling, C., Buhl, R., Brusselle, G., Cruz, A. A., Drazen, J. M., Duijts, L., et al. (2023) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-023-00330-1 · Cited by 361
Self-citationEAACI Guidelines on Allergen Immunotherapy: House dust mite‐driven allergic asthma
Agache, I., Lau, S., Akdis, C. A., Smolinska, S., Bonini, M., Cavkaytar, O., Flood, B., Gajdanowicz, P., Izuhara, K., Kalayci, O., et al. (2019) · Allergy · doi:10.1111/all.13749 · Cited by 319
Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
Strehl, C., Ehlers, L., Gaber, T., & Buttgereit, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01744 · Cited by 308
The Global Initiative for Asthma (GINA): 25 years later
Boulet, L.-P., Reddel, H. K., Bateman, E., Pedersen, S., FitzGerald, J. M., & O'Byrne, P. M. (2019) · European Respiratory Journal · doi:10.1183/13993003.00598-2019 · Cited by 296
Self-citationHardy, J., Baggott, C., Fingleton, J., Reddel, H. K., Hancox, R. J., Harwood, M., Corin, A., Sparks, J., Hall, D., Sabbagh, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31948-8 · Cited by 280
Self-citation
Metadata
- Authors
- O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-17
- Volume
- 378
- Issue
- 20
- Pages
- 1865-1876
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2804974483
- Cited by
- 645
- References
- 32
- FWCI
- 47.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.